CSL
CSL Limited is a global biotechnology company specializing in the development, manufacturing, and marketing of life-saving biotherapies, vaccines, and diagnostic products. Its core business revolves around plasma-derived therapies, which treat a range of serious medical conditions, and recombinant technologies. CSL holds a leading market position in several therapeutic areas, leveraging its extensive research and development capabilities and global manufacturing and distribution network to deliver innovative healthcare solutions.
Short position
CSL (ASX:CSL) has 1.01% of its shares on issue reported as short positions as of 5 Oct 2026, or about 4,858,977 shares. Over the past 30 days that figure has fallen 0.43 percentage points, and over 90 days it has fallen 0.27 percentage points. Its highest recorded short interest was 3.33% in June 2010. CSL is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4CSL (CSL) company profile
Profile, insiders and operations
Company
AI-generated research profile of Csl
Operations exposure
VictoriaSome operations exposure (estimate)
Basis: Melbourne R&D and manufacturing
Coarse bands are AI estimates based on public company information.
CSL intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links